European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

Development of a TB vaccine in Africa

Objective

Despite the millions of deaths from tuberculosis each year and the threat of increased drug resistance, tuberculosis vaccine development has been hugely under-resourced. We set out here to evaluate the safety and immunogenicity of new subunit Constructs in Africa, a continent in desperate need of an effective tuberculosis vaccine. We shall employ two attenuated poxvirus vectors, modified virus Ankara and the FP9 adios strain that both have a marked capacity to boost pre-existing T cell responses, each expressing the secreted mycobacterium antigen, Ag85A. We shall initially test the vaccines individually at different doses and then in heterogonous prime-boost regimes to identify an immunisation regime that works well both in non-infected individuals and also in those already infected by M tuberculosis, a post-exposure vaccination group. In parallel we shall measure the incidence of tuberculosis infection and disease in various high-risk cohorts in this region to identify a group in whom tuberculosis subunit vaccines may in future be tested efficiently.

Call for proposal

Data not available

Coordinator

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
EU contribution
No data
Address

DAKAR
Senegal

See on map

Total cost
No data

Participants (3)